Cell and gene therapy developers continually encounter significant hurdles during the fill & finish phase—challenges best illustrated by manual workflows that are prone to variability, risk of contamination, and limited scalability. This whitepaper, authored by Charles River Laboratories, provides an objective examination of Xiogenix’s ARES X20+ Fill & Finish System and its potential to redefine this critical stage of drug manufacturing.
Through clear analysis and case data, the report demonstrates how a fully automated, closed-single-use platform can:
-
Eliminate labor-intensive, error-prone manual steps
-
Strengthen temperature and process controls
-
Deliver consistent, high-precision fill accuracy
-
Support larger batch sizes with minimal additional risk
Register now to receive the full whitepaper and discover how an automated fill & finish solution can accelerate development timelines, enhance product quality, and help bring life-saving therapies to more patients.